Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spruce Biosciences Inc (NQ: SPRB )

0.5274 -0.0126 (-2.33%)
Streaming Delayed Price Updated: 12:33 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spruce Biosciences Inc

< Previous 1 2 3 4 5 6 7 Next >
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Spruce Biosciences, Inc.
Via Business Wire
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024
SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Spruce Biosciences Recognized as a Bay Area Best Place to Work
From Spruce Biosciences, Inc.
Via Business Wire
Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool. 
Via Benzinga
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
From Spruce Biosciences, Inc.
Via Business Wire
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024
SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in May Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Pfizer Q1 Earnings and Revenues Beat Estimates
PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago. 
Via Talk Markets
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall
Spruce Biosciences faces setbacks as tildacerfont trials fail primary endpoints, raising concerns about drug efficacy and compliance. Analysts downgrade ratings and adjust price targets amid... 
Via Benzinga
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.35% to 38,905.20 while the NASDAQ fell 0.13% to 16,156.28.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; Dollar General Posts Upbeat Earnings
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.30% to 38,926.22 while the NASDAQ fell 0.44% to 16,107.04. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
US Stocks Higher; Producer Prices Rise 0.6% In February
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Is Altria Giving Up on Anheuser-Busch (BUD) Stock?
Anheuser-Busch stock is falling on Thursday following news that 10% holder Altria is selling a portion of its stake in BUD shares. 
Via InvestorPlace
Why Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?
Spruce Biosciences' latest CAH studies: CAHmelia-203 & CAHptain-205. Discover insights on tildacerfont's efficacy, safety, and pharmacokinetics in adult & pediatric CAH patients. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is Fisker (FSR) Stock Down 41% Today?
Fisker stock is falling hard on Thursday as FSR investors react to reports that the EV company is preparing to file for bankruptcy. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.